- •Ketogenic diets are safe in MS patients with sustained, low NfL levels while on diet.
- •Those with greater evidence of serologic ketosis exhibit greater improvement in NfL.
- •Reduction in serum bicarbonate on ketogenic diet directly correlates with NfL level.
Ketogenic diets have anti-inflammatory and neuroprotective properties which make these diets an attractive complimentary treatment approach for patients living with multiple sclerosis (MS). The objective of this study was to assess the impact of ketogenic diets on neurofilament light chain (NfL), a biomarker of neuroaxonal injury.
Thirty-nine subjects with relapsing MS completed a 6-month ketogenic diet intervention. NfL levels were assayed at both baseline (pre-diet) and 6-months on-diet. In addition, ketogenic diet study participants were compared to a cohort (n = 31) of historical, untreated MS controls.
Baseline (pre-diet) mean NfL was 5.45 pg/ml (95% CI 4.59 - 6.31). After 6 months on ketogenic diet, mean NfL was not significantly changed (5.49 pg/ml; 95% CI 4.82 - 6.19). Compared to untreated MS controls (mean 15.17 pg/ml), NfL levels for the ketogenic diet cohort were relatively low. MS subjects with higher levels of ketosis (as measured by serum beta-hydroxybutyrate) exhibited greater reductions in NfL between baseline and 6-months on ketogenic diet.
Ketogenic diets do not worsen biomarkers of neurodegeneration in relapsing MS patients, with stable, low levels of NfL observed throughout the diet intervention. Subjects with greater biomarkers of ketosis experienced a higher degree of improvement in serum NfL.
Clinical trial identifier
NCT03718247 – “Utilization of the Ketogenic Diet in Patients with Relapsing-Remitting MS” https://clinicaltrials.gov/ct2/show/NCT03718247.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis.EBioMedicine. 2018; 36: 293-303
- Impact of dietary intervention on serum neurofilament light chain in multiple sclerosis.Neurol. Neuroimmunol. Neuroinflamm. 2022; 9
- Pilot study of a ketogenic diet in relapsing-remitting MS.Neurol. Neuroimmunol. Neuroinflamm. 2019; 6: e565
- Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.J. Neurol. Neurosurg. Psychiatry. 2022;
- Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.JAMA Neurol. 2019; 76: 1359-1366
- Blood neurofilament light levels segregate treatment effects in multiple sclerosis.Neurology. 2020; 94: e1201-e1e12
- Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis.Ann. Neurol. 2017; 81: 857-870
Dupuis N., Curatolo N., Benoist J.F., Auvin S. Ketogenic diet exhibits anti-inflammatory properties. 0916.
- Inflammation-Mediated Memory Dysfunction and Effects of a Ketogenic Diet in a Murine Model of Multiple Sclerosis.PLoS ONE. 2012; 7: e35476
- Identification of altered metabolic pathways during disease progression in EAE mice via metabolomics and lipidomics.Neuroscience. 2019; 416: 74-87
- Ketogenic diet attenuates oxidative stress and inflammation after spinal cord injury by activating Nrf2 and suppressing the NF-κB signaling pathways.Neurosci. Lett. 2018; 683: 13-18
- The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.Nat. Med. 2015; 21: 263-269
Published online: March 25, 2023
Accepted: March 25, 2023
Received in revised form: March 22, 2023
Received: November 23, 2022
© 2023 Elsevier B.V. All rights reserved.